Stock BIOG B BIOGAIA AB
Add to a list
To use this feature you must be a member
Log inSign up

Company BioGaia AB

Equities

BIOG B

SE0017769995

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 08:59:50 03/05/2024 pm IST 		5-day change 1st Jan Change
114.1 SEK +0.80% Intraday chart for BioGaia AB -0.95% +12.75%
03/04 Nordic Shares Rose Wednesday; BW LPG Led Increases DJ
28/03 Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss DJ

Business Summary

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

Number of employees: 210

Sales per Business

SEK in Million2022Weight2023Weight Delta
Pediatrics
78.2 %
868 78.7 % 1,014 78.2 % +16.72%
Adult Health
21.2 %
230 20.9 % 275 21.2 % +19.56%
Other
0.6 %
5 0.5 % 8 0.6 % +43.63%

Sales per region

SEK in Million2022Weight2023Weight Delta
Americas
38.6 %
369 33.5 % 501 38.6 % +35.49%
EMEA
36.1 %
492 44.5 % 468 36.1 % -4.76%
Asia Pacific
23.5 %
223 20.2 % 304 23.5 % +36.37%
Sweden
1.8 %
20 1.8 % 23 1.8 % +18.78%

Managers

Managers TitleAgeSince
Peter Michael Rothschild FOU
 Founder 74 01/90/01
Theresa Agnew CEO
 Chief Executive Officer 58 01/23/01
Alexander Kotsinas DFI
 Director of Finance/CFO 57 05/19/05
Gianfranco Grompone CTO
 Chief Tech/Sci/R&D Officer 49 01/20/01
Linda Hägglund SAM
 Sales & Marketing 51 01/20/01
Jakob Axelsson PRN
 Corporate Officer/Principal 50 01/17/01
Caroline Mofors LAW
 General Counsel 52 01/23/01
Sebastian Heimfors PRN
 Corporate Officer/Principal 50 01/21/01
Angelika Kjelldorff HRO
 Human Resources Officer 55 01/19/01

Members of the board

Members of the board TitleAgeSince
David E. R. Dangoor BRD
 Director/Board Member 75 01/03/01
Peter Michael Rothschild FOU
 Founder 74 01/90/01
Barbro Fridén BRD
 Director/Board Member 68 05/23/05
Bénédicte Flambard BRD
 Director/Board Member 51 01/22/01
Anthon Jahreskog BRD
 Director/Board Member 44 01/15/01
Vesa Veikko Koskinen BRD
 Director/Board Member 45 05/23/05
Vanessa Rothschild BRD
 Director/Board Member 38 01/20/01
Outi Helena Armstrong BRD
 Director/Board Member 57 05/23/05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 3,703,340 0 0 80.06 %
Stock B 1 97,278,970 80,845,985 ( 83.11 %) 0

Shareholders

NameEquities%Valuation
EQT Partners AB
11.48 %
11,164,630 11.48 % 130 M kr
Fjärde AP-fonden
8.296 %
8,070,000 8.296 % 94 M kr
Premier Fund Managers Ltd.
5.190 %
5,048,743 5.190 % 59 M kr
Alfred Berg Kapitalförvaltning AB
3.634 %
3,535,000 3.634 % 41 M kr
Teknik Innovation Norden Fonder AB
3.438 %
3,344,175 3.438 % 39 M kr
Cargill, Inc.
3.084 %
3,000,000 3.084 % 35 M kr
Livförsäkringsbolaget Skandia, ömsesidigt
2.626 %
2,554,535 2.626 % 30 M kr
Handelsbanken Fonder AB
2.544 %
2,474,781 2.544 % 29 M kr
Tredje AP-fonden
2.507 %
2,438,907 2.507 % 28 M kr
AMF Fonder AB
2.340 %
2,275,985 2.340 % 27 M kr
NameEquities%Valuation
Annwall & Rothschild Investments AB
100.00 %
3,703,340 100.00 % 43 M kr

Company contact information

BioGaia AB

Kungsbroplan 3

112 27, Stockholm

+46 8 555 293 00

http://www.biogaia.com
address BioGaia AB(BIOG B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for BioGaia AB

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
114.1 SEK
Average target price
140 SEK
Spread / Average Target
+22.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
BIOGAIA AB Stock BioGaia AB
+12.75% 1.07B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.45% 40.51B
BIOGEN INC. Stock Biogen Inc.
-15.94% 31.67B
UCB Stock UCB
+52.66% 24.62B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.50% 15.65B
INCYTE CORPORATION Stock Incyte Corporation
-14.38% 12.07B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.97B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.81B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-4.33% 8.5B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. BIOG B Stock
  4. Company BioGaia AB